Equities

Allovir Inc

ALVR:NAQ

Allovir Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.619
  • Today's Change-0.363 / -36.93%
  • Shares traded2.16m
  • 1 Year change-60.32%
  • Beta0.6331
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments184234248
Total Receivables, Net0.210.160.05
Total Inventory------
Prepaid expenses3.499.105.18
Other current assets, total------
Total current assets188243253
Property, plant & equipment, net2.193331
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.120.611.10
Total assets191277287
LIABILITIES
Accounts payable6.763.008.36
Accrued expenses212127
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.740.182.75
Total current liabilities282438
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total172823
Total liabilities455361
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital802691522
Retained earnings (accumulated deficit)(656)(466)(297)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.06)(0.47)(0.16)
Total equity146225225
Total liabilities & shareholders' equity191277287
Total common shares outstanding1149364
Treasury shares - common primary issue001.96
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.